| 词条 | Lampalizumab |
| 释义 |
| type = mab | image = | alt = | mab_type = Fab | source = zu/o | target = CFD | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = Intravitreal | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number = 1278466-20-8 | ATC_prefix = none | ATC_suffix = | PubChem = | DrugBank = | IUPHAR_ligand = 8294 | ChemSpiderID = none | KEGG = D10440 | C=2068 | H=3214 | N=546 | O=676 | S=13 | molecular_weight = 46.96 kg/mol }}Lampalizumab (INN) is an antigen-binding fragment of a humanized monoclonal antibody that binds to complement factor D; it was developed as a potential treatment of geographic atrophy (atrophy of the retinal cells, retinal pigment epithelium, and choriocapillaris) secondary to age-related macular degeneration.[1][2] One of the two Phase 3 clinical trials (Spectri) was interrupted on September 8, 2017 due to failure to meet primary end point.[3] The second Phase 3 clinical trial (Chroma) also failed to meet its primary end point.[4] These two failures have called into question whether complement inhibition is a sound strategy for geographic atrophy.[5] References1. ^{{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107 | journal = WHO Drug Information | volume = 26 | issue = 2 | year = 2012 | url = http://www.who.int/medicines/publications/druginformation/innlists/Final_PL107.pdf | format=PDF}} {{monoclonals for immune system}}{{monoclonal-antibody-stub}}2. ^Statement On A Nonproprietary Name Adopted By The USAN Council - Lampalizumab, American Medical Association. 3. ^{{Cite web|url=http://www.roche.com/investors/updates/inv-update-2017-09-08b.htm|title=Roche provides update on first lampalizumab phase III study for geographic atrophy, an advanced form of age-related macular degeneration|website=www.roche.com|language=en|access-date=2017-09-14}} 4. ^{{Cite web|url=https://www.roche.com/media/store/statements.htm|title=Statement on Chroma Study|website=www.roche.com|language=en|access-date=2017-11-10}} 5. ^{{cite journal|last1=Dolgin|first1=E|title=Age-related macular degeneration foils drugmakers.|journal=Nature Biotechnology|date=9 November 2017|volume=35|issue=11|pages=1000–1001|doi=10.1038/nbt1117-1000|pmid=29121027}} 2 : Monoclonal antibodies|Abandoned drugs |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。